Navigation Links
Mindray Medical to Acquire a Controlling Stake in Hunan Changsha TDR Biotech
Date:12/20/2011

SHENZHEN, China, Dec. 20, 2011 /PRNewswire-Asia-FirstCall/ -- Mindray Medical International Limited (NYSE: MR), a leading developer, manufacturer and marketer of medical devices worldwide, announced today an agreement to acquire a controlling stake of Hunan Changsha Tiandiren Biotech Co., Ltd. ("TDR"). The terms of the agreement were not disclosed as the transaction is non-material to Mindray's financial statements.

Founded in 1997 and based in Hunan, China, TDR is a domestic manufacturer of microbiology analysis solutions that specialize in microbial identification and antibiotic susceptibility testing (ID/AST) and the blood culture system. Clinical laboratories use the ID/AST system to identify microbes and perform antibiotic susceptibility testing, while they use the blood culture system to recover pathological organisms. The rapid reporting of ID/AST test results and a continuous-monitoring blood culture system can result in better antibiotic management. Last year, the market for ID/AST and blood culture system was estimated at approximately $139 million in China. It is expected to grow 15-20% annually. Internationally, the market was estimated at $2.25 billion in 2010 and is expected to grow 5% annually.

Through this transaction, Mindray will be able to combine its strong platforms in sales, manufacturing, R&D, quality assurance and other resources with TDR's technology and expertise in the microbiology analysis business. TDR's strength in reagents is expected to complement Mindray's strength in analyzers.

"This transaction continues to show our commitment to expand the IVD product portfolio," said Mr. Minghe Cheng, Mindray's Chief Strategic Officer. "TDR's products will be a great addition to our existing IVD product line. Microbiology analysis is an important segment within IVD. It is an emerging yet promising category in China, based on favorable dom
'/>"/>

SOURCE Mindray Medical International Limited
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Mindray Medical to Acquire a Controlling Stake in Zhejiang Greenlander Information Technology
2. Mindray to Launch New DC-T6 Ultrasound System at RSNA
3. Mindray Announces Partnership with Epiphany Cardiography Products, LLC
4. Mindray to Hold Annual General Meeting in Hong Kong on December 19, 2011
5. Mindray Announces Up to $100 Million Share Repurchase Program
6. Mindray Announces Third Quarter 2011 Financial Results
7. Mindray Medical to Exhibit at MEDICA 2011 in Dusseldorf, Germany from November 16-19, 2011
8. Mindray Medical to Exhibit New Products at 66th China International Medical Equipment Fair
9. Mindray to Report Third Quarter 2011 Financial Results on November 7, 2011
10. Mindray Introduces Enhancements for M Series Ultrasound Platforms at ASA
11. Mindray Announces Expansion of its A Series Anesthesia Portfolio
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... 2015  Soligenix, Inc. (OTCQB: SNGX) (Soligenix ... products that address unmet medical needs in the ... it has completed enrollment of the additional subjects, ... earlier this year, into the company,s Phase 2 ... defense regulator (IDR) and is being evaluated as ...
(Date:8/31/2015)... LAKE, N.J. and STAMFORD, Conn. ... U.S. pharmaceutical subsidiary of Eisai Co., Ltd., and Purdue ... a worldwide collaboration agreement for the development and commercialization ... dual orexin receptor antagonist entering Phase III clinical development ... the terms of the agreement, Eisai and Purdue Pharma ...
(Date:8/31/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/wmn42n/prescription_pain ) has ... Drugs - Including Opioid, Anticonvulsant, Injectable/ Inhaled, Topical/ ... Opportunities: 2015 - 2020 Analysis and Forecasts" ... is defined as an unpleasant sensory and emotional ... At some point, everyone experiences pain. Pain may ...
Breaking Medicine Technology:Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 2Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 3Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 4Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 5Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 6Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 2Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 3Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 4Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 5Prescription Pain Drugs Including Opioid, Anticonvulsant, Injectable/ Inhaled, Topical/ Transdermal, Medical Marijuana - 2015-2020 Analysis and Forecasts 2Prescription Pain Drugs Including Opioid, Anticonvulsant, Injectable/ Inhaled, Topical/ Transdermal, Medical Marijuana - 2015-2020 Analysis and Forecasts 3
... Pharmaceuticals, Inc. , a private, clinical-stage biopharmaceuticals company ... announced today that it has initiated the first ... vaccine candidate, marking the fourth human clinical trial ... program.  The Phase I dose-escalation study will assess ...
... Mass., Sept. 16 Generex Biotechnology Corporation (NasdaqCM: GNBT ... respect of the technologies and development products of its ... presentations were made at the conference Gene based ... 13 and 14, 2010 in Vienna, Austria and at ...
Cached Medicine Technology:LigoCyte Pharmaceuticals Initiates First Clinical Trial for Bivalent Intramuscular Norovirus Vaccine 2LigoCyte Pharmaceuticals Initiates First Clinical Trial for Bivalent Intramuscular Norovirus Vaccine 3Generex Announces Presentations of Novel Vaccine Strategies 2Generex Announces Presentations of Novel Vaccine Strategies 3
(Date:8/31/2015)... RESTON, Va. (PRWEB) , ... August 31, 2015 ... ... the nation’s leading nonprofit authority on the use of health IT to ... its annual fall conference, WEDI-Con 2015 . Taking place at the Hyatt ...
(Date:8/31/2015)... Riviera Beach, FL (PRWEB) , ... August 31, 2015 , ... ... Wilander to their growing list of major sports figures who are finding joint pain ... Slam titles, and former #1 men’s tennis player in the world said, “For the ...
(Date:8/31/2015)... ... August 31, 2015 , ... PartnerTech hosted prospective ... and provided a tour of their North American facility following the S.M.A.R.T Community ... companies expanding business in the U.S. , The PartnerTech Inc. North American ...
(Date:8/31/2015)... ... August 31, 2015 , ... ERT, ... cloud analytics and workflow solutions will demonstrate multiple prototypes from its Innovation Lab ... 22-24, 2015. This is the only European event dedicated to providing case studies ...
(Date:8/31/2015)... ... 2015 , ... Global Digital Community, a UK based Digital ... now open in Jacksonville, Florida. , “We researched many opportunities in the ... waterways and beautiful beaches fit perfectly with the environment desired by our team ...
Breaking Medicine News(10 mins):Health News:WEDI Announces Program for Annual Fall Conference: WEDI-Con 2015 2Health News:WEDI Announces Program for Annual Fall Conference: WEDI-Con 2015 3Health News:Mats Wilander, 7 Grand Slam Title Winner and Tennis Legend, Now Plays Without Joint Pain 2Health News:Mats Wilander, 7 Grand Slam Title Winner and Tennis Legend, Now Plays Without Joint Pain 3Health News:PartnerTech Supports Economic Growth as Host 2Health News:ERT to Demonstrate Innovation Lab Prototypes at European PRO / eCOA Congress 2Health News:ERT to Demonstrate Innovation Lab Prototypes at European PRO / eCOA Congress 3Health News:Global Digital Opens USA Digital Agency Hub 2
... By itself, dry skin isn,t a,medical worry, but serious ... and inflammation. This is one problem that hasn,t suffered,from ... dozens of,creams and lotions for dry skin. But what ... are few and far between. The fact,is that despite ...
... SAN JOSE, Calif., Jan. 29 The Coalition ... Michon as its,new Chief Executive Officer. Michon has ... of development, a key area of importance in,leadership ... will lead the,CPF,s next phase of growth, including ...
... Ray Society to add more journals and images to ... the open access publisher of peer-reviewed biomedical research has ... the GoldMiner collection. The collection now numbers over 170,000 ... search for radiology images by quickly matching search criteria ...
... Increased Resources Are an,Essential First Step, WASHINGTON, ... risk, as are the regulatory systems that oversee ... FDA Science Board report being,presented at a House ... the deficiencies to soaring demands on the FDA; ...
... that it takes 50,000 lying side by side to equal ... to be highly accurate vehicles for administering medicines and other ... what happens to the tubes after they discharge their medical ... Now, Stanford researchers, who spent months tracking the tiny tubes ...
... control the climate but unless we harness the powers of ... a losing battle, according to an article in the February ... the atmosphere. Arrogant organisms that we are, it is easy ... says Dr Dave Reay from the University of Edinburgh. In ...
Cached Medicine News:Health News:Tips for Dry Winter Skin, From the Harvard Health Letter 2Health News:CPF Appoints Mishka Michon Chief Executive Officer 2Health News:FDA Advisors Declare 'FDA Science and Mission at Risk' 2Health News:FDA Advisors Declare 'FDA Science and Mission at Risk' 3Health News:FDA Advisors Declare 'FDA Science and Mission at Risk' 4Health News:New nanotube findings by Stanford researchers give boost to potential biomedical applications 2Health News:New nanotube findings by Stanford researchers give boost to potential biomedical applications 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: